The Use of Novel Non-Vitamin K Antagonist Oral Anticoagulants Following Closure of the Left Atrial Appendage: Preliminary Results of Clinical Follow-Up

References

• KirchhofP, BenussiS, KotechaD, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS [published correction appears in rev esp cardiol (Engl Ed). 2017 Nov;70(11):1031]. Rev Esp Cardiol. 2017;70(1):50. doi:10.1016/j.rec.2016.11.03328038729
   PubMed Web of Science ®Google Scholar
• GuériosÊE, ChamiéF, MontenegroM, et al. First results of the Brazilian registry of percutaneous left atrial appendage closure. Arq Bras Cardiol. 2017;109(5):440–447. doi:10.5935/abc.2017015029069203
   PubMed Web of Science ®Google Scholar
• HuangCX, ZhangZ, HuangDJ, et al. Current knowledge and management recommendations of atrial fibrillation: 2018. Chin J Cardiac Arrhythmias. 2018;22(4):279–346.
   Google Scholar
• YangB, YangQ, XieQ. Predictive factors of recurrence of atrial fibrillation in patients accepting catheter ablation. J Pract Med. 2016;32(22):3717–3720.
   Google Scholar
• SawJ, FahmyP, AzzaliniL, et al. Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure. J Cardiovasc Electrophysiol. 2017;28(4):396–401. doi:10.1111/jce.1316828128883
   PubMed Web of Science ®Google Scholar
• AcampaM, LazzeriniPE, GuideriF, TassiR, Lo MonacoA, MartiniG. Inflammation and atrial electrical remodelling in patients with embolic strokes of undetermined source. Heart Lung Circ. 2019;28(6):917–922. doi:10.1016/j.hlc.2018.04.29429887417
   PubMed Web of Science ®Google Scholar
• BorianiG, PieragnoliP, BottoGL, et al. Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial. Europace. 2019;21(4):636–644. doi:10.1093/europace/euy28630649270
   PubMed Web of Science ®Google Scholar
• ReddyVY, DoshiSK, KarS, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964–2975. doi:10.1016/j.jacc.2017.10.02129103847
   PubMed Web of Science ®Google Scholar
• ZhongMZ. Current state and outlook in the diagnosis and treatment of atrial fibrillation. J Pract Med. 2015;31(6):872–875.
   Google Scholar
• FountainRB, HolmesDR, ChandrasekaranK, et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with atrial fibrillation) trial. Am Heart J. 2006;151(5):956–961. doi:10.1016/j.ahj.2006.02.00516644311
   PubMed Web of Science ®Google Scholar
• BergmannMW, BettsTR, SievertH, et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. EuroIntervention. 2017;13(7):877–884. doi:10.4244/EIJ-D-17-0004228606886
   PubMed Web of Science ®Google Scholar
• JiangC, ZhangY, LiSL, et al. Efficacy and safety of percutaneous left atrial appendage occlusion for secondary stroke prevention in patients with atrial fibrillation. Chin Med. 2018;33(01):01–04.
   Google Scholar
• ChenYY, ChenYH, ZhangYH, et al. Use of novel oral anticoagulant left atrial appendage closure: results of peri-operative and short-term clinical follow-up. Chin J Intervent Cardiol. 2018;26(10):547–551.
   Google Scholar
• GloeklerS, SawJ, KoskinasKC, et al. Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. Int J Cardiol. 2017;249:234–246. doi:10.1016/j.ijcard.2017.08.04928882323
   PubMed Web of Science ®Google Scholar
• SchnabelRB, YinX, GonaP, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–162. doi:10.1016/S0140-6736(14)61774-825960110
   PubMed Web of Science ®Google Scholar
• ChenZJ, YiGW. 2016 ESC guidelines for the management of atrial fibrillation developed. J Clin Cardiol. 2016;32(11):1076–1078.
   Google Scholar
• FauchierL, CinaudA, BrigadeauF, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol. 2018;71(14):1528–1536. doi:10.1016/j.jacc.2018.01.07629622159
   PubMed Web of Science ®Google Scholar
• BashirMU, BhagraA, KapaS, McLeodCJ. Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation. Rev Cardiovasc Med. 2019;20(3):129–137. doi:10.31083/j.rcm.2019.03.51731601087
   PubMed Web of Science ®Google Scholar
• FiginiF, MazzoneP, RegazzoliD, et al. Left atrial appendage closure: a single center experience and comparison of two contemporary devices. Catheter Cardiovasc Interv. 2017;89(4):763–772. doi:10.1002/ccd.2667827567013
   PubMed Web of Science ®Google Scholar
• BoninM, MewtonN, RoubilleF, et al. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc. 2018;7(4):e006833. doi:10.1161/JAHA.117.00683329440010
   PubMed Web of Science ®Google Scholar
• ShenZF. Clinical curative of new oral anticoagulants for the treatment of gerontal patients with non-valvular atrial fibrillation. Clin Pract Med. 2018;13(18):96–97.
   Google Scholar
• GuoYS, ZhangHJ, LiXL, et al. Safety and efficacy of dabigatran in long-term anticoagulation in patients with atrial fibrillation. J Pract Med. 2018;34(19):3277–3279.
   Google Scholar
• KirchhofP, BenussiS, KotechaD, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–1678. doi:10.1093/europace/euw29527567465
   PubMed Web of Science ®Google Scholar
• OpacicD, van BragtKA, NasrallahHM, SchottenU, VerheuleS. Atrial metabolism and tissue perfusion as determinants of electrical and structural remodelling in atrial fibrillation. Cardiovasc Res. 2016;109(4):527–541. doi:10.1093/cvr/cvw00726786160
   PubMed Web of Science ®Google Scholar
• BöscheLI, AfshariF, SchöneD, EwersA, MüggeA, GotzmannM. Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device. Clin Cardiol. 2015;38(12):720–724. doi:10.1002/clc.2247826467851
   PubMed Web of Science ®Google Scholar
• EnomotoY, GadiyaramVK, GianniC, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm. 2017;14(1):19–24. doi:10.1016/j.hrthm.2016.10.02027771552
   PubMed Web of Science ®Google Scholar